Skip to main content
PMC home page
World Journal of Hepatology logoLink to World Journal of Hepatology
. 2017 Aug 18;9(23):1001–1007. doi: 10.4254/wjh.v9.i23.1001

MicroRNAs and clinical implications in hepatocellular carcinoma

Amal Ahmed Mohamed 1, Zainab A Ali-Eldin 2, Tamer A Elbedewy 3, Magdy El-Serafy 4, Fatma A Ali-Eldin 5, Hossameldin AbdelAziz 6
PMCID: PMC5569275  PMID: 28878865

Abstract

AIM

To assess the role of some circulating miRNAs (miR-23a, miR-203, miR338, miR-34, and miR-16) as tumor markers for diagnosis of hepatocellular carcinoma (HCC).

METHODS

One hundred and seventy-one subjects were enrolled, 57 patients with HCC, 57 patients with liver cirrhosis (LC) and 57 healthy subjects as control group. Severity of liver disease was assessed by Child Pugh score. Tumor staging was done using Okuda staging system. Quantification of Micro RNA (miR-23a, miR-203, miR338, miR-34, and miR-16) was performed.

RESULTS

All studied miRNA showed significant difference between HCC and cirrhotic patients in comparison to healthy control. miR-23a showed statistically significant difference between HCC and cirrhotic patients being higher in HCC group than cirrhotic. miR-23a is significantly higher in HCC patients with focal lesion size equal or more than 5 cm, patients with multiple focal lesions and Okuda stage III. At cutoff value ≥ 210, miR-23a showed accuracy 79.3% to diagnose HCC patients with sensitivity 89.47% and specificity about 64.91%. At cut off level ≥ 200 ng/mL, serum alpha fetoprotein had 73.68% sensitivity, 52.63% specificity, 43.75% PPV, 80% NPV for diagnosis of HCC.

CONCLUSION

MicroRNA 23a can be used as a screening test for early detection of HCC. Also, it is related to larger size of tumour, late Okuda staging and multiple hepatic focal lesions, so it might be a prognostic biomarker.

Keywords: Hepatocellular carcinoma, MicroRNA, Liver cirrhosis, MiR-23a

Core tip: MicroRNA is promising as diagnostic and prognostic biomarkers. miR-23a can be used in screening of hepatocellular carcinoma (HCC) and it gives better results than alpha fetoprotein. It is also related to more progressive HCC so it can be used as predictor of prognosis.

INTRODUCTION

MicroRNAs (miRNA) are small, non-coding RNAs that negatively regulate gene expression at the post-transcriptional level[1]. miRNA is known to regulate the cell cycle, apoptosis and metastasis[2]. Aberrant miRNA expression contributes to tumorigenesis and cancer progression[3]. miRNA is involved in various biological processes that underlie hepatic tumor formation[1]. Murakami et al[4] was the first to report that hepatic cmalignancy exhibited an abnormal expression pattern of miRNAs as the dysregulation of miRNA expression has been identified as a common characteristic of liver cancer. Later on, a number of studies have confirmed that miRNAs possess important regulatory roles in hepatocarcinogenesis and malignant transformation[5].

Circulating miRNAs that are released from cancerous tissues are stable and readily available for clinical analysis, and therefore may be useful for the first-line detection of cancer[6]. Studies concerning miRNAs appear to show a novel perspective for cancer diagnosis and treatment[2].

Hepatocellular carcinoma (HCC) is characterized by significant morbidity and high mortality rates worlwide[7]. Because of the difficulty of clinical diagnosis at the early stage, only 30%-40% of cases can undergo curative resection[8]. As there are currently no reliable tumor markers or imaging technologies that can accurately diagnose early HCC, the use of circulating miRNAs as a potential tool for HCC detection has become an emerging area of study[6,9]. Many circulating microRNAs were evaluated in liver diseases including miR-122, miR-21, miR-34a, miR-221, miR-23a, miR-216, miR-155, miR-186, miR-150, miR-130b, and miR-214[10]. Our aim is to detect the possibility of using some circulating miRNAs as tumor markers for diagnosis of HCC namely miR-23a, miR-203, miR-338-3p, miR-34, and miR-16.

MATERIALS AND METHODS

This prospective cross sectional study included 171 subjects divided into 3 groups: Group I comprising 57 patients with HCC, Group II comprising 57 patients with liver cirrhosis, Group III 57 healthy subjects as a control group.

Informed written consent was obtained from all participants prior to enrollment in the study and approved by ethical committee of Faculty of Medicine, Tanta University. Patients with other cancers or metastatic liver cancer were excluded. All patients were submitted to detailed history and clinical assessment. Liver cirrhosis was diagnosed on the basis of history, clinical examination, laboratory findings, and abdominal ultrasonography. Severity of liver disease was assessed by Child Pugh score[11]. HCC was diagnosed by abdominal ultrasonography, abdominal triphasic computed tomography and serum Alpha fetoprotein (AFP). Tumor characteristics were detected including tumor size, focal lesion number, site, and portal vein invasion. Tumor staging was done using Okuda staging system[12].

Fasting venous blood samples (5 mL) were collected by trained laboratory technicians. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, total bilirubin levels and creatinine were measured by using SynchronCX4 clinical system. Serumα-fetoprotein levels and viral status (HCV-Ab and HBs Ag) were estimated by serological techniques (Axyam System, Abbott Laboratories). Prothrombin time measurements were performed for all patients; normal time was 12 s [100% concentration and International normalization ratio (INR) of 1]. Complete blood count was done using Automatic blood cell counter model PCE-210N (ERMA INC).

RNA isolation

Total RNA was isolated according to the instructions of the supplier and was further purified using an RN easy mini kit (Qiagen, Valencia, CA, United States).

Quantitative real-time PCR

Quantification of Micro RNA was performed using Taq Man Gene Expression (Applied BiosystemsInc, Foster City, CA, United States). RNAU6 was used as house-keeping gene (endogenous reference cDNA) for all micro RNA in this study. Fractional threshold cycles (CT) were expressing the initial concentration of target sequence. Relative mRNA quantification was calculated using the arithmetic formula 2)-ΔCT, where ΔCT is the difference between the CT of a given target cDNA and an endogenous reference cDNA. Thus, this value yields the amount of the target normalized to an endogenous reference.

Statistical analysis

The collected data were tabulated and analyzed using SPSS version 23 software (SPSS Inc, Chicago, ILL Company). Categorical data were presented as number and percentages while quantitative data were expressed as mean, standard deviation and median. Comparison of continuous data between two groups was made by using unpaired t test for parametric data and Mann-Whitney test for non-parametric data. Comparison of continuous data between more than two groups was made by using one way ANOVA for parametric data and Kruskal-Wallis test for nonparametric data. χ2 test was used for comparison between categorical data. Receiving operating characteristic (ROC) analysis curves and the corresponding area under the curve were calculated for providing the accuracy of the microRNAs and AFP, in diagnosis of HCC. ROC curve was used for estimation of sensitivity (i.e., true positive rate), specificity (i.e., true negative rate), positive predictive value (PPV), negative predictive value (NPV) and cutoff values showing the best equilibrium between sensitivity and specificity were evaluated. The accepted level of significance in this work was stated at 0.05 (P < 0.05 was considered significant).

RESULTS

The demographic data and Child-Pugh scoring of the studied groups are shown in Table 1. Symptoms were elicited by 85.96% of the HCC. Out of the recruited patients, 73.68%, 14.04% and 12.28% were HCV patients, HBV patients and non-HCV non-HBV respectively. Regarding Okuda staging system, 12.28% of HCC patients presented in stage I, 40.35% of HCC patients presented in stage II and 47.37% of HCC patients presented in stage III. Imaging showed that all HCC occurred on top of cirrhosis, ascites was present in 82.46% of the HCC patients and portal vein thrombosis was found in 17.54%. Focal lesions were single in 56.14% of cases, affected the right lobe in 56.14% of cases and their size ranged from 3.2 to 14 cm with a mean of 7.61 ± 3.037 as shown in Table 2. Comparison between all studied groups as regard liver functions tests, and other investigations are shown in Table 3.

Table 1.

Demographic data and Child Pugh scoring of the studied groups n (%)

Variable(s) Group I Group II Group III P value
HCC group (n = 57) Cirrhotic group (n = 57) Control group (n = 57)
Gender
Male 37 (64.91) 39 (68.42) 40 (70.18) 0.8289
Female 20 (35.09) 18 (31.58) 17 (29.82)
Age (mean ± SD) (yr) 55.9 ± 5.194 54.88 ± 9.907 54.3 ± 6.34 0.5087
Child Pugh classification
A 10 (17.54) 15 (26.32) - 0.527
B 18 (31.58) 16 (28.07) -
C 29 (50.88) 26 (45.61) -
Open in a new tab

HCC: Hepatocellular carcinoma.

Table 2.

Imaging characteristics of hepatocellular carcinoma cases

Variables n (%)
Size (mean ± SD) (range) cm 7.61 ± 3.037 (3.2-14)
Portal veins thrombosis Yes 10 (17.54)
No 47 (82.46)
No. of focal lesions Single 32 (56.14)
Multiple 25 (43.86)
Site of focal lesions Right lobe 32 (56.14)
Left lobe 17 (29.82)
Both lobes 8 (14.04)
Okuda stage I 7 (12.28)
II 23 (40.35)
III 27 (47.37)
Open in a new tab

Table 3.

Laboratory characteristics among the studied groups

Variable(s) Group I Group II Group III P P1 P2 P3
HCC group (n = 57) Cirrhotic group (n = 57) Control group (n = 57)
mean ± SD mean ± SD mean ± SD
ALT (U/L) 60.75 ± 32.63 59.04 ± 68.74 30.18 ± 5.48 < 0.0001 < 0.05 < 0.001 < 0.001
AST (U/L) 86.7 ± 35.1 66.77± 32.07 32.79 ± 7.2 < 0.0001 < 0.01 < 0.001 < 0.001
Total bilirubin (mg/dL) 4.48 ± 4.7 5.2 ± 5.59 0.77 ± 0.18 < 0.0001 > 0.05 < 0.001 < 0.001
Serum albumin (g/dL) 2.54 ± 0.38 2.72 ± 0.53 4.05 ± 0.47 < 0.0001 > 0.05 < 0.001 < 0.001
INR 1.48 ± 0.3 1.54 ± 0.72 0.99 ± 0.07 < 0.0001 > 0.05 < 0.001 < 0.001
Serum α-feto protein (ng/mL) 1418.55 ± 2953.2 41.61 ± 15.78 5.8 ± 1.65 < 0.0001 > 0.05 < 0.001 < 0.001
Serum creatinine (mg/dL) 2.2 ± 1.77 1.64 ± 1.23 0.95 ± 0.16 < 0.0001 > 0.05 < 0.001 < 0.001
Hemoglobin (g/dL) 9.72 ± 1.22 10.02 ± 0.89 12.62 ± 1.1 < 0.0001 > 0.05 < 0.001 < 0.001
Platelet (× 109/L) 98.33 ± 30.83 102.32 ± 33.24 220.93 ± 53.14 < 0.0001 > 0.05 < 0.001 < 0.001
Total leucocytic count (× 109/L) 3.17 ± 0.47 3.39 ± 0.50 6.83 ± 2 < 0.0001 > 0.05 < 0.001 < 0.001
Open in a new tab

Regarding miRNA values, the tested miR-23a, miR-203, miR-338, miR-34, and miR-16 showed a statistically significant difference between patients group I and II vs group III. It was found that 23a, 34 and 16 microRNAs were significantly higher in HCC group and cirrhotic group when compared with the control group; but 203 and 338 microRNAs were significantly lower in HCC group and cirrhotic group when compared with the control group. But only miRNA 23a showed statistically significant difference between group I and II, being higher in the HCC group than the cirrhotic group as shown in Table 4.

Table 4.

MicroRNAs levels among the studied groups

Variable(s) Group I Group II Group III P P1 P2 P3
HCC group (n = 57) Cirrhotic group (n = 57) Control group (n = 57)
Median (range) Median (range) Median (range)
MicroRNA 23a 214 (21-218) 211 (21-218) 26 (20-219) < 0.0001 < 0.05 < 0.001 < 0.001
MicroRNA 34 214 (22-220) 211 (24-218) 25 (20-219) < 0.0001 > 0.05 < 0.001 < 0.001
MicroRNA 203 26 (21-219) 26 (20-219) 214 (21-225) < 0.0001 > 0.05 < 0.001 < 0.001
MicroRNA 338 26 (21-219) 26 (21-219) 212 (29-217) < 0.0001 > 0.05 < 0.001 < 0.001
MicroRNA 16 214 (21-225) 213 (24-218) 25 (20-219) < 0.0001 > 0.05 < 0.001 < 0.001
Open in a new tab

P1: Group I vs II; P2: Group I vs III; P3: Group II vs III.

When miRNAs were studied according to the focal lesion characteristics, it was found that 23a microRNA levels were higher in patients with focal lesion size equal to or more than 5 cm, in patients with multiple focal lesions; and in Okuda stage III as shown in Table 5.

Table 5.

Comparison between microRNAs levels in relation to tumour characteristics, α-feto protein level, Okuda staging, and the etiology of liver cirrhosis

MicroRNA 16
 MicroRNA 338
 MicroRNA 203
 MicroRNA 34
 MicroRNA 23a
 n Variable(s)
P-value Range Median P-value Range Median P-value Range Median P-value Range Median P-value Range Median
0.3910 24-217 212 0.3890 24-219 27 0.2571 22-217 24 0.0558 24-215 213 0.0008a 21-213 211 11 Less than 5 cm Size of focal lesions
21-225 214 21-215 25 21-219 26 22-220 215 23-2118 214 46 Equal or more 5 cm
0.3026 23-221 214 0.5352 21-219 26 0.5040 22-219 26 0.8975 24-220 214 0.0001a 21-218 211 32 Single No. of focal lesions
21-225 214 22-215 26 21-29 26 22-2119 215 214-218 215 25 multiple
0.9581 29-218 214 0.9247 22-29 26 0.7767 23-29 26 0.8255 22-219 214 0.0795 210-217 215 10 Present Portal vein thrombosis
21-225 214 21-219 26 21-219 26 24-220 214 21-218 213 47 Absent
0.8881 22-225 214 0.8295 21-219 26 0.0807 21-217 27 0.3367 22-220 215 0.9736 21-218 214 36 Less than 200 ng/mL AFP level
21-221 214 21-215 26 21-219 25 27-219 214 23-217 214 21 Equal or more 200 ng/mL
0.9347 25-217 214 0.1145 24-29 27 0.4488 23-217 26 0.4396 24-215 214 0.0001a 24-213 211 7 Stage I Okuda stage
23-221 214 21-219 24 22-219 27 29-220 214 21-218 211 23 Stage II
21-225 214 22-215 27 21-29 25 22-219 214 211-218 215 27 Stage III
0.1603 23-225 214 0.4405 21-219 26 0.4007 21-219 27 0.7827 24-220 214 0.5433 21-218 214 42 HCV Etiology of liver cirrhosis
21-215 211 21-29 26 24-215 25 210-217 214 23-215 214 8 HBV
25-216 214 24-29 27 23-26 24 22-219 215 210-217 214 7 None
Open in a new tab
a

The first column is variable but is here in this copy the last column. HCV: Hepatitis C virus; HBV: Hepatitis B virus.

At a cut off level of 200 ng/mL, serum AFP in the studied patients had 73.68% sensitivity, 52.63% specificity, 43.75% PPV, and 80% NPV for the diagnosis of HCC. At a cut off level of 210ct, serum microRNA 23a had 89.47% sensitivity, 64.91% specificity, 56.04% PPV, and 92.5% NPV for diagnosis of HCC as shown in Table 6 and Figures 1 and 2.

Table 6.

Sensitivity, specificity, positive prediction value, negative prediction value and accuracy of microRNAs and α-feto protein

Variable(s) Cutoff value Sensitivity% Specificity% Positive predictive value (PPV%) Negative predictive value (NPV%) Accuracy
MicroRNA 23a ≥ 210 89.47% 64.91% 56.04% 92.5% 79.3%
MicroRNA 34 ≥ 210 89.47% 55.26% 50% 91.3% 79.3%
MicroRNA 203 ≥ 24 80.7% 10.53% 31.08% 52.17% 29.6%
MicroRNA 338 ≥ 25 63.16% 16.67% 27.48% 47.5% 26.4%
MicroRNA 16  ≥ 210 87.72% 57.89% 51.02% 90.4% 75.7%
α-feto protein ≥ 200 73.68% 52.63% 43.75% 80% 78.5%
Open in a new tab

PPV: Positive predictive value; NPV: Negative predictive value.

Figure 1.

Figure 1

Open in a new tab

Receiving operating characteristic curve of microRNAs. ROC: Receiving operating characteristic.

Figure 2.

Figure 2

Open in a new tab

Receiving operating characteristic curve of α-feto protein. ROC: Receiving operating characteristic.

DISCUSSION

microRNA is differentially expressed in development of different types of malignancies, including hepatic malignancy[13], which suggests that microRNAs may have a role in carcinogenesis as new oncogenes or tumor-suppressor genes. The presence of microRNAs in serum was first reported in 2008 in cases with large B cell lymphoma[14]. They could be a potential biomarker for diagnosis of tumors[15]. The present study was designed to evaluate the role of some microRNA (23a, 34, 203, 338 and 16) in early diagnosis of HCC. To fulfill this aim 57 HCC patients, 57 patients with liver cirrhosis and 57 healthy controls were enrolled.

In the present work, serum microRNA 23a level was significantly higher in the HCC group in comparison to other groups. Also, it is significantly higher in liver cirrhosis group in comparison to healthy controls. A similar result was obtained by Li et al[16]. They reported up regulation of microRNA 23a in HCC patients in comparison to liver cirrhosis patients and healthy control. This up-regulation in liver cirrhosis than healthy controls and further up-regulation in HCC patients in comparison to viral hepatitis patients suggests a role of microRNA 23a in the pathogenesis of HCC. A study on resected human HCC tissues found that microRNA-23a down-regulates the expression of interferon regulatory factor-1 in HCC cells[17].

Serum microRNA 34 and microRNA 203 levels were similarly elevated in HCC and liver cirrhosis groups. Many authors found that microRNA 34 expression is increased in hepatic fibrosis[18], HCV infection[19], alcoholic liver disease[20], NAFLD[21,22] and HCC tissues[23-25].

On the contrary, studies on microRNA 203 in HCC tissues found that microRNA 203 is down-regulated in HCC tissue[26,27]. Moreover, studies correlate this down-regulation with recurrence of HCC in liver transplantation[26] and bad prognosis in HCC patients[27]. None of these studies was done on serum; they assessed tissue level of HCC in resected HCC tissues.

Serum microRNA 338 and microRNA 16levels are similarly reduced in HCC patients and liver cirrhosis patients. In line with these findings, many studies concluded reduced tissue expression of miR-338-3p in different types of cancers[28-30]. Studies on HCC showed that miR-338-3pmiR-338-3p was significantly down-regulated in HCC tissues and cell lines compared to the corresponding matched adjacent normal tissues[31,32].

On the contrary, other researchers found that circulating microRNA 338 level increased in HCC patients than liver cirrhosis and controls[33] but their study has a limitation of small sample size (37 HCC patients, 29 cirrhosis patients, and 31 healthy controls).

Serum microRNA 23a level at cutoff value ≥ 210 showed accuracy of 79.3% to differentiate HCC patients from cirrhotic patients and healthy control with high sensitivity about 90%, specificity about 65%, PPV 56% and NPV 92.9. These values are better than those elicited by alpha fetoprotein. The later at a cut off level of 200 ng/mL, had 73.68% sensitivity, 52.63% specificity, 43.75% PPV, and 80% NPV for the diagnosis of HCC. So, serum microRNA 23a can be used as a screening test to diagnose HCC as it showed high sensitivity. To the best of our knowledge no previous studies elicited such finding. A single study that used combination of 13 microRNA including 23a found that HCC on top of chronic HBV infection could be differentiated from chronic HCV infection and healthy control[16]. MicroRNA 23a levels were significantly higher in patients with focal lesion 5 cm or more in size, patients with multiple focal lesions; and Okuda stage III when compared with patients with less advanced HCC disease. Thus it could be used as a prognostic biomarker.

Other studied microRNA factors showed insignificant difference between HCC and liver cirrhosis patients, so they cannot be used as diagnostic markers of HCC. In conclusion, microRNA 23a can be used as a screening test for early detection of HCC. Also, it is related to larger size of tumour, late Okuda staging and multiple hepatic focal lesions, so it might be a prognostic biomarker. Validation study on large scale is needed to confirm these results.

COMMENTS

Background

MicroRNAs are small, non-coding RNAs that negatively regulate gene expression at the post transcriptional level including cell cycle, apoptosis and metastasis. Aberrant miRNA expression contributes to tumorigenesis and cancer progression. Number of studies have confirmed that miRNAs possess important regulatory roles in hepatocarcinogenesis and malignant transformation. Hepatocellular carcinoma (HCC) is characterized by significant morbidity and high mortality rates. Because of the difficulty of early clinical diagnosis, only 30%-40% of cases can undergo curative resection. Circulating miRNAs released from cancerous tissues are stable and readily available for clinical analysis and appear to show a novel perspective for cancer diagnosis.

Research frontiers

Many microRNAs have been studied as biomarkers for diagnosis of malignancies. Yet, role of microRNA in early diagnosis of HCC is not confirmed.

Innovations and breakthroughs

This work demonstrates that miR-23a can be used in screening of liver cancer and it gives better results than alpha fetoprotein. This work showed first demonstration that microRNA 23a could be used as a promising biomarker for HCC patients, even though large scale examination is required. This manuscript would provide important clues for the development of microRNA as biomarkers for HCC.

Applications

MicroRNA 23a can be used as a screening test for early detection of HCC. Also, it is related to larger size of tumour, late Okuda staging and multiple hepatic focal lesions, so it might be a prognostic biomarker. Validation study on large scale is needed to confirm these results.

Peer-review

This manuscript would provide important clues for the development of microRNA as biomarkers for HCC.

Footnotes

Manuscript source: Invited manuscript

Specialty type: Gastroenterology and hepatology

Country of origin: Egypt

Peer-review report classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

Institutional review board statement: The study was approved.

Informed consent statement: All study participants, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: None.

Data sharing statement: No additional data are available.

Peer-review started: February 17, 2017

First decision: April 20, 2017

Article in press: June 20, 2017

P- Reviewer: Yu DY S- Editor: Ji FF L- Editor: A E- Editor: Li D

Contributor Information

Amal Ahmed Mohamed, Biochemistry Department, National Hepatology and Tropical Medicine Research Institute, Cairo 11796, Egypt. amalahmedhcp@yahoo.com.

Zainab A Ali-Eldin, Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo 11331, Egypt.

Tamer A Elbedewy, Department of Internal Medicine, Faculty of Medicine, Tanta University, Tanta 31111, Egypt.

Magdy El-Serafy, Department of Tropical Medicine, Faculty of Medicine, Cairo University, Cairo 11796, Egypt.

Fatma A Ali-Eldin, Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo 11331, Egypt.

Hossameldin AbdelAziz, Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo 11331, Egypt.

References

  • 1.Gong J, Zhang JP, Li B, Zeng C, You K, Chen MX, Yuan Y, Zhuang SM. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene. 2013;32:3071–3079. doi: 10.1038/onc.2012.318. [DOI] [PubMed] [Google Scholar]
  • 2.Gong J, He XX, Tian A. Emerging role of microRNA in hepatocellular carcinoma (Review) Oncol Lett. 2015;9:1027–1033. doi: 10.3892/ol.2014.2816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Zhu Z, Zhang X, Wang G, Zheng H. Role of MicroRNAs in Hepatocellular Carcinoma. Hepat Mon. 2014;14:e18672. doi: 10.5812/hepatmon.18672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25:2537–2545. doi: 10.1038/sj.onc.1209283. [DOI] [PubMed] [Google Scholar]
  • 5.Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology. 2009;50:472–480. doi: 10.1002/hep.22989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Qi J, Wang J, Katayama H, Sen S, Liu SM. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma. 2013;60:135–142. doi: 10.4149/neo_2013_018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.World Health Organization. GLOBOCAN Estimated Cancer Incidence, Mortality and Prevalence Worldwide, 2012. [Google Scholar]
  • 8.Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29:4781–4788. doi: 10.1200/JCO.2011.38.2697. [DOI] [PubMed] [Google Scholar]
  • 9.Chang-Hao Tsao S, Behren A, Cebon J, Christophi C. The role of circulating microRNA in hepatocellular carcinoma. Front Biosci (Landmark Ed) 2015;20:78–104. doi: 10.2741/4299. [DOI] [PubMed] [Google Scholar]
  • 10.Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther. 2013;6:1167–1178. doi: 10.2147/OTT.S36161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649. doi: 10.1002/bjs.1800600817. [DOI] [PubMed] [Google Scholar]
  • 12.Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–928. doi: 10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  • 13.Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell. 2009;136:586–591. doi: 10.1016/j.cell.2009.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672–675. doi: 10.1111/j.1365-2141.2008.07077.x. [DOI] [PubMed] [Google Scholar]
  • 15.Huang FY, Wong DK, Seto WK, Lai CL, Yuen MF. Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. Oncotarget. 2015;6:34941–34952. doi: 10.18632/oncotarget.5472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, Shen HB, Zhang CY, Zen K. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010;70:9798–9807. doi: 10.1158/0008-5472.CAN-10-1001. [DOI] [PubMed] [Google Scholar]
  • 17.Yan Y, Liang Z, Du Q, Yang M, Geller DA. MicroRNA-23a downregulates the expression of interferon regulatory factor-1 in hepatocellular carcinoma cells. Oncol Rep. 2016;36:633–640. doi: 10.3892/or.2016.4864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Li WQ, Chen C, Xu MD, Guo J, Li YM, Xia QM, Liu HM, He J, Yu HY, Zhu L. The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats. FEBS J. 2011;278:1522–1532. doi: 10.1111/j.1742-4658.2011.08075.x. [DOI] [PubMed] [Google Scholar]
  • 19.Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One. 2011;6:e23937. doi: 10.1371/journal.pone.0023937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Meng F, Glaser SS, Francis H, Yang F, Han Y, Stokes A, Staloch D, McCarra J, Liu J, Venter J, et al. Epigenetic regulation of miR-34a expression in alcoholic liver injury. Am J Pathol. 2012;181:804–817. doi: 10.1016/j.ajpath.2012.06.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, Kellum JM, Min H, Luketic VA, Sanyal AJ. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology. 2008;48:1810–1820. doi: 10.1002/hep.22569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, Sugimoto K, Ohashi K, Teradaira R, Inoue T, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 2013;424:99–103. doi: 10.1016/j.cca.2013.05.021. [DOI] [PubMed] [Google Scholar]
  • 23.Bernardi C, Soffientini U, Piacente F, Tonetti MG. Effects of microRNAs on fucosyltransferase 8 (FUT8) expression in hepatocarcinoma cells. PLoS One. 2013;8:e76540. doi: 10.1371/journal.pone.0076540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Chiu LY, Kishnani PS, Chuang TP, Tang CY, Liu CY, Bali D, Koeberl D, Austin S, Boyette K, Weinstein DA, et al. Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkers. J Gastroenterol. 2014;49:1274–1284. doi: 10.1007/s00535-013-0890-2. [DOI] [PubMed] [Google Scholar]
  • 25.Dang Y, Luo D, Rong M, Chen G. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One. 2013;8:e61054. doi: 10.1371/journal.pone.0061054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Chen HY, Han ZB, Fan JW, Xia J, Wu JY, Qiu GQ, Tang HM, Peng ZH. miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. Med Oncol. 2012;29:1859–1865. doi: 10.1007/s12032-011-0031-9. [DOI] [PubMed] [Google Scholar]
  • 27.Liu Y, Ren F, Rong M, Luo Y, Dang Y, Chen G. Association between underexpression of microrna-203 and clinicopathological significance in hepatocellular carcinoma tissues. Cancer Cell Int. 2015;15:62. doi: 10.1186/s12935-015-0214-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Guo B, Liu L, Yao J, Ma R, Chang D, Li Z, Song T, Huang C. miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a. Mol Cancer Res. 2014;12:313–321. doi: 10.1158/1541-7786.MCR-13-0507. [DOI] [PubMed] [Google Scholar]
  • 29.Li P, Chen X, Su L, Li C, Zhi Q, Yu B, Sheng H, Wang J, Feng R, Cai Q, et al. Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. PLoS One. 2013;8:e66782. doi: 10.1371/journal.pone.0066782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Chen X, Pan M, Han L, Lu H, Hao X, Dong Q. miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a. FEBS Lett. 2013;587:3729–3737. doi: 10.1016/j.febslet.2013.09.044. [DOI] [PubMed] [Google Scholar]
  • 31.Wang G, Sun Y, He Y, Ji C, Hu B, Sun Y. MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4) Int J Clin Exp Pathol. 2015;8:337–344. [PMC free article] [PubMed] [Google Scholar]
  • 32.Chen JS, Liang LL, Xu HX, Chen F, Shen SL, Chen W, Chen LZ, Su Q, Zhang LJ, Bi J, et al. miR-338-3p inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma cells. Oncotarget. 2016 doi: 10.18632/oncotarget.10138. Epub ahead of print. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Chen Y, Chen J, Liu Y, Li S, Huang P. Plasma miR-15b-5p, miR-338-5p, and miR-764 as Biomarkers for Hepatocellular Carcinoma. Med Sci Monit. 2015;21:1864–1871. doi: 10.12659/MSM.893082. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from World Journal of Hepatology are provided here courtesy of Baishideng Publishing Group Inc

RESOURCES